Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Recently, we genetically modified MSCs with high mobility group box 1 (HMGB1) and demonstrated the high efficacy of these cells in treating graft atherosclerosis.
|
30867070 |
2019 |
Atherosclerosis
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Then, high-mobility group box 1 (HMGB1) was verified as a target of miR-126-5p and its expression was increased in AS.
|
31204352 |
2019 |
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b> These results indicate that CUMS exacerbates atherosclerosis is likely via HMGB1-mediated downregulation of PPARγ/LXRα-ABCA1 through TLR4.
|
30881312 |
2019 |
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Recent studies showed that HMGB1 is one of the important pathophysiological mechanisms in the occurrence and development of atherosclerosis.
|
30204458 |
2018 |
Atherosclerosis
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Experiments in vivo found glycyrrhizin significantly attenuated the LPS /high-fat diet-induced atherosclerosis and serum HMGB 1 levels in mice.
|
30371306 |
2018 |
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Therefore, the findings suggested that HMGB1 participated in oxidative stress-induced atherosclerosis presumably by targeting multipotent vascular stem cells.
|
29951536 |
2018 |
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Thus, this study investigated the relationship between HMGB1 and vascular inflammation in Apoe-/- mice and whether glycyrrhizin (GLY), a small inhibitor of HMGB1, could have atheroprotective effects in AS.
|
30650406 |
2018 |
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
HMGB1 may modulate Treg/Th17 balance in patients with AS through inducing Treg cell apoptosis and promoting cell differentiation of Th17.
|
30271090 |
2018 |
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Pyroptosis is characterized by rapid plasma membrane rupture, with the consequent release of intracellular contents and pro-inflammatory mediators, including interleukin (IL)-1β, IL-18, and the alarmin HMGB-1.Recent studies have shown that pyroptosis may be involved in atherosclerosis and play an important role in atherosclerotic lesion instability.
|
29129476 |
2018 |
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Taken these together, it was implied that miR-328 ameliorated ox-LDL-induced endothelial cells injury through targeting HMGB1 in atherosclerosis.
|
30324654 |
2018 |
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
This paper, based on biochemical and mass spectrometry proteomic data, highlights the role of the heat shock proteins (HSPs), high-mobility group box 1 (HMGB1) protein and S100 proteins as main alarmins involved in maintaining and amplifying atherosclerosis, diabetes and cancer inflammation.
|
27840210 |
2017 |
Atherosclerosis
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
High mobility group box 1 (HMGB1) and receptor for advanced glycation end products (RAGE) cause the activation of intracellular signaling, gene expression, and production of inflammatory cytokines and have been linked to many inflammatory disease states such as diabetes mellitus and atherosclerosis.
|
28092162 |
2017 |
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
A large number of studies report that HMGB1 and Th17 cells may promote atherosclerosis progression, whereas Treg cells may play a protective role in atherosclerosis; thus, alterations in the Treg/Th17 ratio may exist in atherosclerosis diseases.
|
26830200 |
2016 |
Atherosclerosis
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Inhibition of HMGB1 expression in addition to sodium ferulate treatment might be a more effective therapeutic approach for atherosclerosis.
|
25561283 |
2015 |
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
HMGB1 has been associated with divergent clinical conditions such as sepsis, rheumatoid arthritis and atherosclerosis.
|
26605648 |
2015 |
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
We demonstrated, for the first time, that HMGB1 is a potential inducer of IFN-γ-producing Th17-cell bias, and that IFN-γ-producing Th17 cells might be one of the pathogenic factors in atherosclerosis.
|
26520896 |
2015 |
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Therapeutic blockade of HMGB1 reduced the development of diet-induced atherosclerosis in ApoE knockout mice.
|
26202300 |
2015 |
Atherosclerosis
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Vehicle-treated ApoE(-/-) mice exhibited significant increases in aortic inflammation and atherosclerosis as well as enhanced expression of HMGB1, RAGE, VCAM-1, and MCP-1 in aortic tissues as compared to the wild-type mice.
|
23564080 |
2013 |
Atherosclerosis
|
0.300 |
Therapeutic
|
disease |
RGD |
To observe the effect of simvastatin on the expression of high mobility group box-1 protein (HMGB1) and morphology of atherosclerotic plaques in atherosclerotic rats, to ascertain whether HMGB1 plays a role in the preventive mechanism of simvastatin from atherosclerosis (AS).
|
20519084 |
2010 |
Atherosclerosis
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
HMGB1 expression by activated vascular smooth muscle cells in advanced human atherosclerosis plaques.
|
17502242 |
2007 |
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
This provides new insights into the role of HMGB1 in VSMCs, suggesting it may be essential for the progression of atherosclerosis.
|
16807371 |
2006 |
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Thus, HMG1 has all the hallmarks of a molecule that can promote atherosclerosis and restenosis after vascular damage.
|
11257120 |
2001 |